TRANSCODE THERAPEUTICS INC (RNAZ)
US89357L3033 - Common Stock
Which stocks are experiencing notable movement on Wednesday?
Stay up-to-date with the latest market trends one hour before the close of the markets on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements.
Let's take a look at the stocks that are in motion in today's session.
Traders are paying attention to the gapping stocks in Wednesday's session. Let's dive into which stocks are experiencing notable gaps.
Let's delve into the US markets on Wednesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
These stocks are moving in today's pre-market session
As the US market prepares to open on Wednesday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split
TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split
TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split...
TransCode Therapeutics, Inc. Announces $8 Million Private Placement
TransCode Therapeutics, Inc. Announces $8 Million Private Placement
TransCode Therapeutics, Inc. Announces $8 Million Private Placement...
TransCode Therapeutics Announces 1-for-33 Reverse Stock Split
Split designed to achieve compliance with Nasdaq minimum bid price requirements
TransCode Therapeutics Announces 1-for-33 Reverse Stock Split
TransCode Therapeutics Announces 1-for-33 Reverse Stock Split...
TransCode Therapeutics Open Letter to Shareholders
TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance
TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance
TransCode Therapeutics Announces Nasdaq Extension to Re-gain Compliance ...
TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology
TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology
TransCode Therapeutics Completes Initial Dosing of First Co-hort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology ...
TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate...
TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against Metastatic Cancer
Study demonstrates that TransCode’s lead therapeutic candidate, TTX-MC138, reduces tumor cell capacity for self-renewal
TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate
Grant awarded by the National Cancer Institute (NCI) of the NIH to support clinical development of lead therapeutic candidate, TTX-MC138
TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate
TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate...
RNAZ Stock Earnings: TransCode Therapeutics Misses EPS for Q2 2024
RNAZ stock results show that TransCode Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.
RNAZ Stock Earnings: TransCode Therapeutics Misses EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips TransCode Therapeutics (NASDAQ:RNAZ) just reported results for the second quart...
TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation
TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation
TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation ...
TransCode Therapeutics, Inc. Announces Closing of Public Offering
TransCode Therapeutics, Inc. Announces Closing of Public Offering
Boston, MA — July 24, 2024 — TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), a clinical-stage RNA oncology company committed...